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SUMMARY
Background—Selective cyclooxygenase-2 (COX-2) inhibitors have been linked to cardiac
death. The mechanism for this adverse effect appears to be by ischemic insult; however another
mechanism could involve hyperkalemia. The objective of this study was to determine the effects
of selective COX-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs)
on serum potassium concentration and the electrocardiogram.
Methods—A retrospective cohort study was conducted using propensity score matching of
patients from an inner-city academic medical center at Indianapolis, Indiana. Two hundred and
two patients prescribed selective COX-2 inhibitors were matched to 202 patients prescribed non-
selective NSAIDs using propensity scores methods. Outcomes included change in serum
potassium concentration from baseline and the risk of an abnormal electrocardiogram.
Results—Compared to patients prescribed non-selective NSAIDs, those prescribed a selective
COX-2 inhibitor had a higher risk of serum potassium increase greater than 5 mEq/L (OR, 2.56;
95%CI, 1.03–6.36). However, patients prescribed selective COX-2 inhibitors had no greater risk
of electrocardiogram abnormality (OR, 1.16; 95%CI, 0.74–1.82).
Conclusions—Selective COX-2 inhibitors may have a greater risk of hyperkalemia than non-
selective NSAIDs. This study was exploratory with small numbers of patients. Further studies are
needed to confirm these results and any association with cardiovascular events.
Keywords
hyperkalemia; NSAIDs; selective COX-2 inhibitors; retrospective cohort study; propensity score
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used widely for acute and chronic
arthritis. Adverse gastrointestinal effects associated with NSAIDs have led to the
development of selective cyclooxygenase-2 (COX-2) inhibitors, which are better tolerated
by the gastrointestinal tract. However, selective COX-2 inhibitors, with the possible
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exception of celecoxib, are associated with adverse cardiovascular events such as
myocardial infarction, stroke, and sudden cardiac death.1,2 These adverse effects led to the
withdrawal from the market of two selective COX-2 inhibitors, namely rofecoxib in 2004
and valdecoxib in 2005. The potential for non-selective NSAIDs to cause such
cardiovascular effects continues to be debated. Although evidence suggests that selective
COX-2 inhibitors increase thrombotic cardiac events,2 other mechanisms could play a role.
For example, NSAIDs are known to cause hyperkalemia,3 which in patients with pre-
existing renal insufficiency or cardiovascular disease could lead to electrocardiogram
abnormalities, arrhythmia, and sudden cardiac death.4
Hyperkalemia from NSAIDs has been the subject of several case reports.5–11 Also, acute
interventional studies have reported that NSAIDs reduce the renal excretion of potassium.
12–14 One small uncontrolled observational study found an increase in serum potassium
concentrations with indomethacin.15 However, to our knowledge, no study has examined
the effects of COX-2 inhibitors compared to other NSAIDs while controlling for important
confounders and determined the risk of arrhythmia. Therefore, the objective of this study
was to investigate whether selective COX-2 inhibitors are associated with an increase in
serum potassium concentration and abnormalities in the electrocardiogram compared to non-
selective NSAIDs using propensity score methods.
METHODS
Design and subjects
This retrospective cohort study included adult patients who received their first prescription
of NSAID from the general medicine practice of Wishard Health Services in Indianapolis,
Indiana. Wishard is city-county health center affiliated with the Indiana University School of
Medicine. We used the Regenstrief Medical Record System (RMRS) to identify eligible
patients and collect data on relevant variables. The RMRS is an electronic medical record
system that captures prescriptions, laboratory test results (including electrographic results),
and other clinical data.16
We used a new user design that has been recently suggested to detect early-onset adverse
effects.17 The index date was defined as the date of the first NSAID prescription between
1993 and 2006. Patients did not have an active prescription for any NSAIDs during the year
preceding the starting index date. The study was approved by the Institutional Review
Boards at the University of North Carolina at Chapel Hill and Indiana University–Purdue
University at Indianapolis.
Data analysis
Serum potassium concentrations and electrocardiogram results were collected within the
years before and after the start date of the first prescription of an NSAID. Information was
collected on relevant confounders at baseline. The end date of follow-up was defined as 1
year after the first prescription or 30 days after the last dispensed prescription, whichever
was less.
Propensity score matching was used to minimize selection bias by balancing covariates
between comparison groups of patients prescribed COX-2 or non-selective NSAIDs.
Propensity scores were calculated using SAS PROC LOGISTIC (SAS Institute, Inc., Cary,
North Carolina). Mahalanobis metric matching without replacement was used since it
produced good balance in covariates between comparison groups.18 A caliper of one-
quarter of the standard deviation of the propensity score was used in the match. To assess
the covariate balance, we used χ2 tests for categorical variables and t-tests for continuous
variables.
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Outcomes included the absolute change in serum potassium concentration before and after
the index date and the risk of experiencing a serum potassium concentration >5 mEq/L. The
first potassium concentration after the index date was selected because the effects of
NSAIDs on renal function (including their effect on potassium homeostasis) happen within
days to a week.12 In addition, physicians may alter treatments based on any increase in
potassium. The secondary outcome of the study was the risk of an abnormal
electrocardiogram (EKG) after receipt of NSAID. An abnormal EKG was defined as any
deviation from normal as interpreted by the physician.
Covariates
Based on previous literature, the models included covariates likely to affect serum potassium
concentrations or the use of NSAIDs including age, race, gender, and baseline serum
potassium concentration. Models controlled for the following diagnoses: rheumatoid
arthritis, osteoarthritis, coronary artery disease or myocardial infarction, stroke or transient
ischemic attack, arrhythmia, asthma or chronic obstructive pulmonary disease, renal
insufficiency, cirrhosis with ascites, systemic lupus erythematosus, diabetes mellitus, and
congestive heart failure. To minimize bias introduced by variations in the time between
baseline serum potassium concentration and the index date, time was included in the model.
The analysis controlled for the use of medications known to be associated with an increase
in potassium concentration including angiotensin-converting enzyme inhibitors, angiotensin
II antagonists, diuretics, and potassium supplements. After matching on propensity score, a
variable was included in the final model to control the time from the index date to the first
measurement of serum potassium in order to reduce the potential for a temporal
measurement bias.
RESULTS
A total of 1985 patients were prescribed selective COX-2 inhibitors (n = 213) or non-
selective NSAIDs (n = 1772) and met inclusion criteria. Baseline characteristics differed
between patients in the selective COX-2 inhibitor group compared to those receiving non-
selective NSAIDs (Table 1). Patients receiving selective COX-2 inhibitors were more likely
to be older, a woman, and have a diagnosis of hypertension or coronary artery disease.
Based on their propensity scores, 202 patients from the selective COX-2 inhibitor group
were matched to 202 patients from the group receiving non-selective NSAIDs. Table 1
shows that propensity score matching resulted in similar covariate distributions between the
two treatment groups. Patients had a mean age of 62 ± 12 years and 84% were women.
Mean potassium concentrations (SD) before and after the index date for the selective COX-2
inhibitor group were 4.15 ± 0.48 mEq/L (range: 3.0–5.7) and 4.25 ± 0.56 mEq/L (range:
2.9–6.2) after the index date and for the non-selective NSAIDs these values were 4.07 ±
0.45 mEq/L (range: 2.7–5.3) and 4.05 ± 0.49 mEq/L (range: 2.4–5.7). Mean absolute pre–
post change in potassium concentrations (±SD) in the selective COX-2 inhibitor group was
0.09 ± 0.57 mEq/L (range: −1.7–2.0) and for the non-selective NSAIDs the mean change in
serum potassium was −0.01 ± 0.53 mEq/L (range: −1.5–1.7).
Crude estimates, before using the propensity score methods, indicated that the risk of
increased potassium concentration was not statistically different between groups (Table 2).
However, after controlling for background characteristics using propensity score matching,
patients who had been prescribed a selective COX-2 inhibitor had a mean estimated increase
in serum potassium concentration of 0.15 mEq/L (p = 0.002) compared with patients
prescribed non-selective NSAIDs. Serum potassium concentrations >5 mEq/L occurred in
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17 patients prescribed selective COX-2 inhibitors and seven patients prescribed non-
selective NSAIDs (OR, 2.56; 95%CI, 1.03–6.36). However, patients prescribed selective
COX-2 inhibitors had no greater risk of abnormal EKG compared to those prescribed non-
selective NSAIDs (OR, 1.16; 95%CI, 0.74–1.82; n = 62 in the selective COX-2 inhibitors
group and n = 56 in the non-selective NSAIDs).
DISCUSSION
This is the first observational study to explore the association between selective COX-2
inhibitors and increased serum potassium concentrations using the propensity score
matching method. The results suggest that patients prescribed selective COX-2 inhibitors
may have a greater risk for increased serum potassium concentrations compared with
patients prescribed non-selective NSAIDs; however, there was no increased risk of
arrhythmia.
The hypothesized mechanism for hyperkalemia associated with NSAIDs is related to the
inhibition of prostacyclin.4 In contrast to COX-1, COX-2 mediates prostacyclin synthesis,
which increases potassium secretion at the distal tubule.4 Thus, selective inhibition of
COX-2 at the distal tubule could explain the greater risk of hyperkalemia associated with
selective COX-2 inhibitors compared with non-selective NSAIDs.
This study has several limitations that should be considered when interpreting the results.
Patients were from a single health system that may not be generalizable to other practices.
Because of small sample sizes, the study was not powered to detect between-group
differences with respect to electrocardiogram abnormalities. Hence, this study should be
replicated in other settings and with greater numbers of patients.
Since the database used in this study captures only prescription NSAID, bias could be
introduced if patients were classified as non-users while they are using over-the-counter
NSAIDs. However, because patients included in this study were provided with their
medications (including those available over the counter) through a prescription assistance
program, it is less likely that they would have purchased over-the-counter NSAIDs.
Furthermore, a recent sensitivity analysis suggested that missing over-the-counter drug
exposure is not a significant source of bias in studies such as ours.19
If confirmed by larger studies in other settings, the results of this study could have important
clinical and policy implications. Before prescribing selective COX-2 inhibitors, physicians
would need to balance the benefits of medication against the risk adverse effects including
hyperkalemia. Patients prescribed selective COX-2 inhibitors who have a predisposing risk
of hyperkalemia or cardiovascular morbidity would need to have their serum potassium
concentration monitored soon after treatment was initiated.
In summary, patients prescribed selective COX-2 inhibitors are at a greater risk for clinically
important increases in potassium serum concentrations compared with patients using non-
selective NSAIDs. Prescribers should consider monitoring serum potassium concentrations
in patients prescribed selective COX-2 inhibitors who are at risk of hyperkalemia or
cardiovascular events. Studies with greater numbers of patients should be conducted in other
patient populations to confirm the results of this study.
KEY POINTS
• Hyperkalemia was associated with selective COX-2 inhibitors; however, there
was no increased risk of arrhythmia
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• Prescribers should consider monitoring serum potassium concentrations in
patients prescribed selective COX-2 inhibitors who are at higher risk of
hyperkalemia
• Future studies with larger numbers of patients should be conducted in other
patient populations to confirm the results of this study
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Unadjusted analysis (n = 1985)
    Incidence of K ≥ 5.0 mEq/L* 1.57 0.92–2.68 0.10
    Risk of abnormal EKG 1.03 0.76–1.40 0.86
Propensity score matching (n = 404)
    Incidence of K ≥ 5.0 mEq/L* 2.56 1.03–6.36 0.04
    Risk of abnormal EKG 1.16 0.74–1.82 0.51
*
Incidence of potassium concentration of ≥5.0 mEq/L after the index date. Incident subjects were those who had baseline potassium concentration
of <5.0 mEq/L and first potassium concentration of ≥5.0 mEq/L after the NSAID was started.
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